Moderna Therapeutics is on a roll. Just 4 short years since the biotech firm launched, and without yet advancing a drug into the clinic, the mRNA therapeutics company has already raised nearly US$1 billion. This includes funding from one of the biggest biotech funding rounds ever — $450 million, raised earlier this year — and from partnerships with AstraZeneca, Merck & Co., Alexion and the US Defense Advanced Research Projects Agency (DARPA). The company's Chief Executive Officer Stéphane Bancel argues that mRNA therapeutics, which are translated in patients into therapeutic proteins and antibodies, could be game changers for industry. He tells Asher Mullard about the opportunity and remaining scientific overhangs of this scientific platform.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Stéphane Bancel. Nat Rev Drug Discov 14, 378–379 (2015). https://doi.org/10.1038/nrd4646
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4646
